花园生物(300401) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥158,982,505.22, representing a 17.39% increase compared to ¥135,433,235.78 in the same period last year[8] - Net profit attributable to shareholders for Q1 2021 reached ¥91,420,363.82, a significant increase of 48.85% from ¥61,418,396.61 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥68,852,669.27, marking a 65.56% increase from ¥41,587,644.62 year-on-year[8] - Basic and diluted earnings per share for Q1 2021 were both ¥0.17, reflecting a 30.77% increase from ¥0.13 in the previous year[8] - The company reported a significant increase in tax expenses by 47.21% to ¥15,198,400.42 from ¥10,324,308.08, driven by higher total profit[26] - The company reported a net profit of CNY 1,428,005,020.94, up from CNY 1,336,584,657.12, reflecting an increase of approximately 7%[87] Cash Flow - The net cash flow from operating activities was ¥77,397,843.98, up 9.32% from ¥70,800,373.59 in the same quarter last year[8] - Cash flow from financing activities showed a net outflow of ¥51,764,416.66, a decrease of 382.90% compared to the previous period[26] - The net increase in cash and cash equivalents was a decrease of 149.89% to -¥81,540,848.95 from -¥32,630,440.62, primarily due to loan repayments[26] - Operating cash inflow for the current period reached ¥415,485,372.30, a significant increase from ¥150,864,932.56 in the previous period[115] - Net cash flow from operating activities was ¥126,663,917.65, compared to a negative cash flow of -¥26,980,473.78 in the previous period[115] - Total cash and cash equivalents at the end of the period were ¥1,077,109,496.43, down from ¥1,158,650,345.38 at the beginning of the period[113] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,396,270,569.44, a decrease of 0.84% from ¥3,425,191,470.28 at the end of the previous year[8] - The company's total current liabilities decreased to CNY 307,655,507.94 from CNY 404,873,605.68, a decline of about 24%[84] - Non-current liabilities also decreased to CNY 87,383,834.34 from CNY 110,507,001.26, representing a reduction of approximately 21%[84] - Total liabilities increased to ¥319,453,671.16 from ¥312,278,031.30, representing a growth of approximately 2.0%[94] Shareholder Information - Net assets attributable to shareholders increased to ¥3,001,231,227.16, up 3.14% from ¥2,909,810,863.34 at the end of the previous year[8] - The total number of ordinary shareholders at the end of the reporting period was 23,142, with the largest shareholder holding 26.20% of the shares[12] Expenses - The company's sales expenses increased by 70.12% to ¥3,145,517.61 from ¥1,849,049.29, attributed to higher sample and advertising costs[23] - Research and development expenses decreased by 36.98% to ¥5,086,875.50 from ¥8,071,303.70, mainly due to reduced material costs for R&D[23] - Total operating costs decreased to ¥78,489,139.00 from ¥86,032,208.99, reflecting a reduction of about 8.5%[97] Investment and Projects - The construction of the Jinxi Technology Park project is progressing steadily, with plans to complete the eastern area by the end of 2021[29] - The core premix project has a total investment of 12,550 million yuan, with 77.72% of the investment completed[33] - The annual production project for 1,200 tons of lanolin cholesterol has reached 51.26% of its investment completion[33] Risks and Challenges - The company faces risks related to project investment, including uncertainties in construction progress and costs[29] - The company has a high demand for skilled professionals in R&D, production, and management, which poses a risk in talent acquisition and retention[29] - The revenue from Vitamin D3 and similar products accounts for a significant portion of total revenue, making the company vulnerable to price fluctuations in these products[29]